ArriVent BioPharma, Inc. (AVBP)

In July 2025, ArriVent announced a $75 million public offering and received a "Strong Sell" rating from Zacks. In August 2025, the company reported positive interim Phase 1b data for firmonertinib and dosed the first patient in a Phase 1 study for ARR-217. In September 2025, ArriVent presented firmonertinib monotherapy data and appointed a Chief Commercial Officer. In November 2025, the company reported its Third Quarter 2025 financial results with an EPS of -$0.83. In December 2025, ArriVent announced the first patient dosed in the global pivotal Phase 3 ALPACCA trial. Analyst ratings have been generally positive, with price targets ranging from $25 to $45. The stock price was $20.80 per share on January 2, 2026, a decline from the previous year, but gained 7.49% on January 13, 2026, rising to $21.97.

There is no information available to indicate demand seasonality for ArriVent BioPharma, Inc.'s products or services. Demand for its products, once approved, would primarily be driven by medical need rather than seasonal fluctuations.

ArriVent BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing differentiated medicines for cancer patients. Their lead candidate, firmonertinib, is being evaluated in clinical trials for EGFRm NSCLC, including a Phase 3 trial. The company is also advancing a pipeline of novel therapeutics, such as next-generation antibody-drug conjugates, with an initial focus on solid tumors.

ArriVent BioPharma, Inc. is headquartered in Newtown Square, Pennsylvania, United States. The company aims to accelerate the global development of innovative biopharmaceutical products by accessing drug candidates from around the world, including China and other emerging biotech hubs.

ArriVent BioPharma generally holds a positive brand reputation within the investment community, largely driven by the potential of its lead asset, firmonertinib. The company has received a consensus rating of "Moderate Buy" from analysts, with a majority issuing "Buy" or "Strong Buy" recommendations. The drug's encouraging efficacy and tolerable safety profile in trials, particularly its CNS activity, are seen as key differentiators. The company's strategy of targeting niche EGFR mutations where competition is less entrenched is also viewed favorably. No specific events that negatively impacted ArriVent BioPharma's reputation in the past year were found in the search results.

ArriVent BioPharma, Inc. is primarily owned by institutional shareholders (93.43%), with insiders holding 25.45% and retail investors holding 0.00%. There are 217 institutional owners and shareholders holding a total of 40,033,533 shares. Major institutional owners include Hillhouse Capital Advisors, Ltd., Infinitum Asset Management LLC, and Suvretta Capital Management LLC. Hillhouse Investment Management Ltd is the largest individual shareholder, owning 4.48 million shares. Insider sentiment has been positive, with high-impact open-market purchases from 11 different insiders over the last year.